<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971201</url>
  </required_header>
  <id_info>
    <org_study_id>WPH20190507</org_study_id>
    <nct_id>NCT03971201</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion</brief_title>
  <official_title>A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>White Plains Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>White Plains Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with HCC with portal vein involvement not involving the bifurcation (vP1-vP3) and no
      evidence of extra-hepatic spread will be enrolled. Patients will be required to have Child's
      A liver function and no significant portal hypertension. Patients will be randomly assigned
      with a 1:1 ratio to either surgery followed by adjuvant sorafenib or sorafenib alone.
      Patients will be followed by serial imaging. The primary end-point is overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial design

      Surgery + sorafenib vs. sorafenib 100 patients per arm Centralized randomization by CRO Need
      to call CRO for treatment allocation Primary end-point - OS Secondary end-point Progression
      free survival (PFS) Randomized 1:1 Stratification Vp1-2 vs. Vp3 AFP ≤400 vs AFP &gt;400
      Intention to treat Surgery aborted or R1-2 resection will remain in surgical arm No cross
      over CT scan chest/abdomen 4 weeks after surgery as post-operative baseline Will not alter
      treatment allocation Will allow for PFS measurement in surgical arm CT scan chest/abdomen
      pelvis Q 12 weeks after initiation sorafenib Patients progressing on sorafenib allowed 2nd
      line treatment Regorafenib or lenvatinib - if approved in China Dose reduction sorafenib as
      per protocol
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2-3 year</time_frame>
    <description>time from randomization to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3-12 months</time_frame>
    <description>time from initiation of intervention until progression as defined by RESIST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery plus sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgical resection followed by adjuvant sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sorafenib only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sorafenib only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatic resection</intervention_name>
    <description>removal of portion of liver containing cancer</description>
    <arm_group_label>Surgery plus sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>sorafenib either as adjuvant therapy after resection or as only treatment</description>
    <arm_group_label>Surgery plus sorafenib</arm_group_label>
    <arm_group_label>sorafenib only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of HCC A) 1st diagnosis of HCC - no prior treatments of HCC B) Diagnosis made by
        contrast enhanced CT or MRI with arterial and portal phases

          1. Arterial enhancement

          2. Venous washout

          3. Expanding/enhancing tumor thrombus seen in portal vein Extent of HCC spread A) Vp1-3
             (Japanese system) - VP1-2 (Cheng criteria - Shanghai) B) No involvement of main portal
             vein Vp4 (Japanese system) - Vp3 Shanghai C) No evidence of extra-hepatic spread in
             abdomen D) No evidence of hepatic vein or vena cava invasion Need for Biopsy A)
             Patients not meeting above criteria B) Absence of underlying liver disease
             Demographics A) Age ≥ 18 Women of reproductive age A) Negative pregnancy test B) Must
             be on birth control for duration of study Able to provide informed consent No prior
             malignancy A) Excluding basal/squamous cell skin cancers B) Excluding superficial
             bladder cancer C) Excluding cervical cancer Underlying liver disease A) HBV, HCV,
             alcohol, or none B) All HBV patients must be placed on anti-viral therapy prior to any
             treatment and continue through entire study C) Co-infection HBV with HCV excluded D)
             HIV infection excluded Liver function/Performance status A) Child's A or B7 liver
             function B) Absence of clinical portal hypertension

        a. Platelet count ≥ 100,000 b. No evidence of varices or splenomegaly on imaging c. No
        ascites ECOG performance status 0-1 Tumor characteristics A) Size of largest tumor ≤ 10cm
        B) &lt;50% of liver volume involved by tumor C) Multiple tumors allowed D) All tumors all
        confined to same lobe as PV involvement E) Hepatic Vein or Inferior Vena Cava involvement
        excluded Non-contrast CT of chest A) No lung metastases B) Involvement of gallbladder and
        diaphragm allowed C) Involvement of omentum allowed D) Involvement of abdominal wall
        allowed E) Involvement of colon, stomach, duodenum excluded

        Exclusion Criteria:

        Unable to provide informed consent Age &lt;18 years Unable to take anti-viral medication for
        hepatitis B Unable to take sorafenib Medically unfit for surgery Prior malignancy other
        than those specifically allowed by study Prior treatment of HCC Tumor characteristics A)
        HCC &gt;10cm B) Bilobar tumor C) Mixed cholangiocarcinoma HCC D) Extra-hepatic tumor E) Tumor
        involving stomach, duodenum or colon F) Tumor involving hepatic veins or vena cava G) Tumor
        involving portal vein bifurcation

        Liver disease A) Liver function decompensated beyond Child's B7 B) Significant portal
        hypertension - splenomegaly, varices, ascites or platelet count &lt;100,000 C) Co-infection
        with HBV and HCV D) Co-infection with HIV ECOG performance status &gt;1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sasan Roayaie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>White Plains Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei-Hua Guan, MD</last_name>
    <phone>+8613501673307</phone>
    <email>weiyu.wang@tigermed.net</email>
  </overall_contact>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>White Plains Hospital</investigator_affiliation>
    <investigator_full_name>Sasan Roayaie</investigator_full_name>
    <investigator_title>International PI</investigator_title>
  </responsible_party>
  <keyword>portal vein invasion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will not be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

